Replication-competent anti-cancer vectors
CA 2378586 C · Owner: Tollefson, Ann E. · Inventors: Tollefson, Ann E.; Doronin, Konstantin; Wold, William S. M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel vectors which are replication-competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 12, 2000 and granted May 3, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 12, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 12, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.